Acer Therapeutics Inc. (NASDAQ: ACER) stock was flourishing in the early morning session. The shares price was up 20.71% to reach $4.43 in the pre-market today.
Recording the history of low and high prices over 52 weeks can provide a lot of information about the stock’s current status and future performance. Today, Acer Therapeutics Inc.’s shares are down 49.38% during the 52 weeks from their high price but are 239.81% higher than their lowest price for the same timeframe. Within the 52 weeks, the stock’s price range was maintained between $1.08 and $7.25.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
What they do…
Acer Pharmaceuticals focuses on acquiring, developing, commercializing, and promoting therapies to treat severe diseases with significant unmet medical needs.
Acer Therapeutics Inc. (NASDAQ: ACER) announced that it had reached full enrollment in its pivotal study, assessing the bioequivalence of ACER-001 by comparing it to BUPHENYL (sodium phenylbutyrate). Urea cycle disorders (UCDs) are being treated with ACER-001, a treatment developed by Acer.
Approximately 36 healthy adults will participate in a single-center, single-blind, randomized crossover trial comparing ACER-001 to BUPHENYL under fed conditions. The first quarter of 2021 is expected to see the results of the trial.
Acer intends to submit to the FDA a request for a pre-NDA meeting on ACER-001 to successfully complete ongoing development activities.
A UCD is a condition that results from genetic abnormalities that result in a deficiency of one of the six enzymes enzymatically catalyzing the ammonia cycle, which can lead to hyperammonemia.
The ACER-001 formulation is a taste-masked powder formed to deliver sodium phenylbutyrate via suspension or oral tablet for immediate release. Using a microencapsulation process, ACER-001 is being developed to treat various metabolic disorders, including UCDs and Maple Syrup Urine Disease (MSUD).
Often investors closely watch the analyst’s sentiment to make their investments.
There are currently four analysts who cover Acer stock, rated Buy by two of them and Overweight by none. During this period, 2 analysts rated it Hold, and no analyst rated it Underweight or Sell. An overall look at the ratings reveals that Acer Therapeutics Inc. (Acer) stock is rated as Overweight on average.